中重度激素抵抗性甲状腺眼病患者的药物治疗
一项2018至2022年全国多中心回顾性病例对照研究,比较替妥木单抗或托珠单抗治疗中重度激素抵抗性甲状腺眼病(TED)的疗效与安全性;替妥木单抗组24周突眼应答81%、复视缓解45.5%,激素初治对照组结果相当,托珠单抗仅6例,作者认为需进一步评估长期反应与副作用。
要点
- 替妥木单抗组24周突眼应答81%、复视缓解45.5%、疾病失活85.7%、转为轻度58.3%。
- 替妥木单抗激素抵抗组与激素初治对照组结果相当,亚组间无显著差异。
- 托珠单抗仅6例,24周突眼应答50%、复视缓解16.7%、疾病失活100%、转为轻度75%。
核心结论
- 替妥木单抗和托珠单抗改善了既往激素治疗失败的中重度TED患者的炎症。
- 替妥木单抗激素抵抗病例在突眼和复视方面的改善与替妥木单抗激素初治对照组相似。
- 作者认为需进一步评估这些药物在激素抵抗性TED中的长期反应和副作用特征。
研究设计与样本
- 2018至2022年在一全国多中心健康系统内开展的回顾性病例对照研究。
- 37例中重度激素抵抗性TED患者接受替妥木单抗或托珠单抗治疗(病例),与接受同类治疗的激素初治患者(对照)比较。
- 因缺乏接受托珠单抗治疗的激素初治患者,分析中未纳入托珠单抗对照组。
- 在第0、12、24、52周评估突眼、复视、临床活动度评分(CAS)和疾病严重度(欧洲Graves眼病组分类)。
主要发现
- 31例接受替妥木单抗(13例病例和18例对照),6例接受托珠单抗(均为病例)。
- 平均年龄57岁(标准差±14.3),TED中位病程11.5个月(四分位距[IQR]:7.2-17.7),中位超出突眼4 mm(IQR:2-8),超出按性别和种族正常上限。
- 第24周替妥木单抗病例中81%有突眼应答(减少≥2 mm)、45.5%复视缓解、85.7%疾病失活(CAS<3)、58.3%转为轻度疾病严重度。
- 替妥木单抗对照组结果相当,亚组间无显著差异。
- 托珠单抗病例中50%有突眼应答、16.7%复视缓解、100%疾病失活、75%转为轻度疾病。
关键数值与推荐
- 突眼应答定义为突眼减少≥2 mm。
- 疾病失活定义为临床活动度评分(CAS)<3。
临床怎么用
- 原文未据此给出推荐。
局限性
- 因缺乏接受托珠单抗治疗的激素初治患者,分析中未纳入托珠单抗对照组。
- 作者认为需进一步评估这些药物在激素抵抗性TED中的长期反应和副作用特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Corticosteroid therapy is often employed in thyroid eye disease (TED), but its efficacy is variable. Teprotumumab and tocilizumab have been considered as effective alternatives. This study aims to evaluate their clinical outcomes and safety in patients with steroid-resistant TED. Methods: A retrospective case-control study was conducted between 2018 and 2022 within a national multicenter health system. Thirty-seven patients with moderate to severe steroid-resistant TED treated with teprotumumab or tocilizumab (cases) were compared with steroid-naïve patients treated with similar therapy (controls). Due to lack of steroid-naïve patients treated with tocilizumab, a control subgroup for tocilizumab was not included in the analysis. Demographic and clinical characteristics were described. Proptosis, diplopia, clinical activity score (CAS), and disease severity (European Group on Graves' orbitopathy classification) were evaluated at weeks 0, 12, 24, and 52 after therapy initiation. Results: Thirty-one patients received teprotumumab (13 cases and 18 controls) and 6 received tocilizumab (cases). The mean age was 57 years (standard deviation ±14.3), median duration of TED was 11.5 months (interquartile range [IQR]: 7.2-17.7), and median excess proptosis was 4 mm (IQR: 2-8) above the upper limit of normal for sex and race. At week 24, in the teprotumumab cases, 81% had proptosis response (reduction of ≥2 mm), 45.5% resolution of diplopia, 85.7% disease inactivation (CAS <3), and 58.3% reverted to mild disease severity. There were comparable results in teprotumumab controls, with no significant differences between subgroups. In the tocilizumab cases, 50% had a proptosis response, 16.7% resolution of diplopia, 100% disease inactivation, and 75% returned to mild disease. In the teprotumumab cases, there was a trend toward worsening proptosis and diplopia between weeks 24 and 52. In the same time frame, the tocilizumab cases had a trend toward worsening diplopia, disease activity, and severity. In the teprotumumab subgroup, 46.2% experienced otic changes and 23.1% hyperglycemia. In the tocilizumab subgroup, there were no reported adverse events. Conclusions: Teprotumumab and tocilizumab improved inflammation in patients with moderate to severe TED who had failed previous steroid therapy. Additionally, the teprotumumab cases demonstrated similar improvement in proptosis and diplopia to the teprotumumab controls. Further evaluation, particularly regarding the long-term response and side effect profile, of these medications in steroid-resistant TED is needed.
引用
- Toro-Tobon D, Rachmasari KN, Bradley EA, et al. Medical Therapy in Patients with Moderate to Severe, Steroid-Resistant, Thyroid Eye Disease. Thyroid. 2023. PMID: 37515425. doi:10.1089/thy.2023.0167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。